Photo of David E. Fisher,  MD, PhD

David E. Fisher, MD, PhD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 643-5428


Dfisher3@Partners.org

David E. Fisher, MD, PhD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Edward Wigglesworth Professor of Dermatology, Dermatology, Harvard Medical School
  • Chief, Dermatology, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

DF/HCC ASSOCIATIONS

  • Member, Center Scientific Council

Research Abstract

Our lab focuses on two areas: analysis of a lineage specifying transcription factor, Microphthalmia; and mechanisms of p53-dependent apoptosis. Microphthalmia is a helix-loop-helix transcription factor which is essential to normal melanocyte, osteoclast, and mast cell development and function. We have identified its role as a major signaling intermediate in pathways activated by Steel/c-Kit, M-CSF/c-fms, and melanocyte stimulating hormone. Its expression and function may also be of importance in melanoma growth and has now been shown to be of considerable diagnostic utility. Our studies on p53 and apoptosis revolve around the importance of the p53 tumor suppressor in mediating a decision between growth arrest and apoptotic death following cellular stress. Because of its unique ability to trigger arrest in untransformed fibroblasts vs. apoptosis in oncogene transformed fibroblasts, its function offers a built in therapeutic window for tumor selective killing. To understand the mechanistic basis for its apoptotic activity we have devised a cell free system in which p53 protein appears to trigger a cascade resulting in caspase activation. Cellular extracts are being fractionated and the apoptotic intermediates are being isolated. This strategy has also uncovered potential inhibitory activities in extracts from certain tumors. The identification and characterization of these factors may add to our understanding of the regulation of cancer cell death and provide potential therapeutic targets.

Publications

Powered by Harvard Catalyst
  • Liu XS, Genet MD, Haines JE, Mehanna EK, Wu S, Chen HI, Chen Y, Qureshi AA, Han J, Chen X, Fisher DE, Pandolfi PP, Yuan ZM. ZBTB7A suppresses melanoma metastasis by transcriptionally repressing MCAM. Mol Cancer Res 2015. PubMed
  • Goldberg J, Fisher DE, Demetri GD, Neuberg D, Allsop S, Fonseca C, Nakazaki Y, Nemer D, Raut CP, George S, Morgan JA, Wagner AJ, Freeman GJ, Ritz J, Lezcano C, Mihm MC, Canning C, Hodi FS, Dranoff G. Biologic Activity of Autologous, Granulocyte-Macrophage Colony Stimulating Factor Secreting Alveolar Soft Parts Sarcoma and Clear Cell Sarcoma Vaccines. Clin Cancer Res 2015. PubMed
  • Salma N, Song JS, Arany Z, Fisher DE. Transcription Factor Tfe3 Directly Regulates Pgc-1Alpha in Muscle. J Cell Physiol 2015. PubMed
  • Zheng B, Fisher DE. Metabolic vulnerability in melanoma: a ME2 (me too) story. J Invest Dermatol 2015; 135:657-9. PubMed
  • Lauss M, Haq R, Cirenajwis H, Phung B, Harbst K, Staaf J, Rosengren F, Holm K, Aine M, Jirström K, Borg Å, Busch C, Geisler J, Lønning PE, Ringnér M, Howlin J, Fisher DE, Jönsson G. Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation. J Invest Dermatol 2015. PubMed
  • Dadras SS, Lin RJ, Razavi G, Kawakami A, Du J, Feige E, Milner DA, Loda MF, Granter SR, Detmar M, Widlund HR, Horstmann MA, Fisher DE. A novel role for microphthalmia-associated transcription factor-regulated pigment epithelium-derived factor during melanoma progression. Am J Pathol 2014; 185:252-65. PubMed
  • Lo JA, Fisher DE. The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Science 2014; 346:945-9. PubMed
  • Lee JH, Fisher DE. Melanocyte stem cells as potential therapeutics in skin disorders. Expert Opin Biol Ther 2014; 14:1569-79. PubMed
  • Choi YS, Fisher DE. UV and melanoma: the TP53 link. Cell Res 2014; 24:1157-8. PubMed
  • Hsiao JJ, Fisher DE. The roles of microphthalmia-associated transcription factor and pigmentation in melanoma. Arch Biochem Biophys 2014. PubMed
  • Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW, McMahon M, Flaherty KT, Fisher DE, Sharpe AH, Wargo JA. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res 2014. PubMed
  • Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, Frederick DT, Barzily-Rokni M, Straussman R, Haq R, Fisher DE, Mesirov JP, Hahn WC, Flaherty KT, Wargo JA, Tamayo P, Garraway LA. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. 2014. PubMed
  • Sullivan RJ, Fisher DE. Understanding the Biology of Melanoma and Therapeutic Implications. Hematol Oncol Clin North Am 2014; 28:437-453. PubMed
  • Luo X, Mitra D, Sullivan RJ, Wittner BS, Kimura AM, Pan S, Hoang MP, Brannigan BW, Lawrence DP, Flaherty KT, Sequist LV, McMahon M, Bosenberg MW, Stott SL, Ting DT, Ramaswamy S, Toner M, Fisher DE, Maheswaran S, Haber DA. Isolation and molecular characterization of circulating melanoma cells. Cell Rep 2014. PubMed
  • Saenger YM, Magidson J, Liaw B, de Moll E, Harcharik S, Fu Y, Wassmann K, Fisher DE, Kirkwood JM, Oh WK, Friedlander P. Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab. Clin Cancer Res 2014. PubMed
  • Haq R, Fisher DE, Widlund HR. Molecular Pathways: BRAF Induces Bioenergetic Adaptation by Attenuating Oxidative Phosphorylation. Clin Cancer Res 2014. PubMed
  • Shtivelman E, Davies MQ, Hwu P, Yang J, Lotem M, Oren M, Flaherty KT, Fisher DE. Pathways and therapeutic targets in melanoma. 2014. PubMed
  • Chen H, Weng QY, Fisher DE. UV Signaling Pathways within the Skin. J Invest Dermatol 2014. PubMed
  • Lee JH, Chen H, Kolev V, Aull KH, Jung I, Wang J, Miyamoto S, Hosoi J, Mandinova A, Fisher DE. High-throughput, high-content screening for novel pigmentation regulators using a keratinocyte/melanocyte co-culture system. Exp Dermatol 2014; 23:125-9. PubMed
  • Dreze M, Calkins AS, Gálicza J, Echelman DJ, Schnorenberg MR, Fell GL, Iwai S, Fisher DE, Szüts D, Iglehart JD, Lazaro JB. Monitoring repair of UV-induced 6-4-photoproducts with a purified DDB2 protein complex. PLoS ONE 2014; 9:e85896. PubMed
  • Levine D, Fisher DE. Current status of diagnostic and prognostic markers in melanoma. Methods Mol Biol 2013; 1102:177-97. PubMed
  • Roider EM, Fisher DE. The impact of MITF on melanoma development: news from bench and bedside. J Invest Dermatol 2013; 134:16-7. PubMed
  • Frederick DT, Salas Fragomeni RA, Schalck A, Ferreiro-Neira I, Hoff T, Cooper ZA, Haq R, Panka DJ, Kwong LN, Davies MA, Cusack JC, Flaherty KT, Fisher DE, Mier JW, Wargo JA, Sullivan RJ. Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics. PLoS ONE 2014; 9:e101286. PubMed
  • Praetorius C, Grill C, Stacey SN, Metcalf AM, Gorkin DU, Robinson KC, Van Otterloo E, Kim RS, Bergsteinsdottir K, Ogmundsdottir MH, Magnusdottir E, Mishra PJ, Davis SR, Guo T, Zaidi MR, Helgason AS, Sigurdsson MI, Meltzer PS, Merlino G, Petit V, Larue L, Loftus SK, Adams DR, Sobhiafshar U, Emre NC, Pavan WJ, Cornell R, Smith AG, McCallion AS, Fisher DE, Stefansson K, Sturm RA, Steingrimsson E. A polymorphism in IRF4 affects human pigmentation through a tyrosinase-dependent MITF/TFAP2A pathway. Cell 2013; 155:1022-33. PubMed
  • Cooper ZA, Frederick DT, Juneja VR, Sullivan RJ, Lawrence DP, Piris A, Sharpe AH, Fisher DE, Flaherty KT, Wargo JA. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology 2013; 2:e26615. PubMed
  • Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 2013; 31:3182-90. PubMed
  • Haq R, Fisher DE. Improving apoptotic responses to targeted therapy. 2013; 4:1331. PubMed
  • Fisher DE, Geller AC. Disproportionate burden of melanoma mortality in young U.S. men: the possible role of biology and behavior. JAMA Dermatol 2013; 149:903-4. PubMed
  • Liu S, Wang J, Su Y, Guerrero C, Zeng Y, Mitra D, Brooks PJ, Fisher DE, Song H, Wang Y. Quantitative assessment of Tet-induced oxidation products of 5-methylcytosine in cellular and tissue DNA. Nucleic Acids Res 2013. PubMed
  • Alves CP, Moraes MH, Sousa JF, Pontes CL, Ramão A, Yokoyama S, Trindade DM, Fisher DE, Espreafico EM. Myosin-Va Contributes to Manifestation of Malignant-Related Properties in Melanoma Cells. J Invest Dermatol 2013. PubMed
  • Morgan AM, Lo J, Fisher DE. How does pheomelanin synthesis contribute to melanomagenesis?: Two distinct mechanisms could explain the carcinogenicity of pheomelanin synthesis. Bioessays 2013. PubMed
  • Korman JB, Fisher DE. Developing melanoma therapeutics: overview and update. 2013; 5:257-71. PubMed
  • Haq R, Fisher DE. Targeting melanoma by small molecules: Challenges ahead. Pigment Cell Melanoma Res 2013. PubMed
  • Fink EC, Fisher DE. BRAF and MC1R in melanoma: different in head and neck tumors? J Invest Dermatol 2013; 133:878-80. PubMed
  • Balk SJ, Fisher DE, Geller AC. Teens and indoor tanning: a cancer prevention opportunity for pediatricians. Pediatrics 2013; 131:772-85. PubMed
  • Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, Frederick DT, Hurley AD, Nellore A, Kung AL, Wargo JA, Song JS, Fisher DE, Arany Z, Widlund HR. Oncogenic BRAF regulates oxidative metabolism via PGC1留 and MITF. Cancer Cell 2013; 23:302-15. PubMed
  • Haq R, Yokoyama S, Hawryluk EB, Jönsson GB, Frederick DT, McHenry K, Porter D, Tran TN, Love KT, Langer R, Anderson DG, Garraway LA, Duncan LM, Morton DL, Hoon DS, Wargo JA, Song JS, Fisher DE. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A 2013; 110:4321-6. PubMed
  • Balk SJ, Fisher DE, Geller AC. Stronger laws are needed to protect teens from indoor tanning. Pediatrics 2013; 131:586-8. PubMed
  • Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, Lizée G, Murphy GF, Hwu P, Flaherty KT, Fisher DE, Wargo JA. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013; 19:1225-31. PubMed
  • Shoag J, Haq R, Zhang M, Liu L, Rowe GC, Jiang A, Koulisis N, Farrel C, Amos CI, Wei Q, Lee JE, Zhang J, Kupper TS, Qureshi AA, Cui R, Han J, Fisher DE, Arany Z. PGC-1 coactivators regulate MITF and the tanning response. Mol Cell 2013; 49:145-57. PubMed
  • Mitra D, Luo X, Morgan A, Wang J, Hoang MP, Lo J, Guerrero CR, Lennerz JK, Mihm MC, Wargo JA, Robinson KC, Devi SP, Vanover JC, D'Orazio JA, McMahon M, Bosenberg MW, Haigis KM, Haber DA, Wang Y, Fisher DE. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature 2012; 491:449-53. PubMed
  • Jalili A, Wagner C, Pashenkov M, Pathria G, Mertz KD, Widlund HR, Lupien M, Brunet JP, Golub TR, Stingl G, Fisher DE, Ramaswamy S, Wagner SN. Dual Suppression of the Cyclin-Dependent Kinase Inhibitors CDKN2C and CDKN1A in Human Melanoma. Journal of the National Cancer Institute 2012; 104:1673-9. PubMed
  • Geller AC, Balk SJ, Fisher DE. Stemming the tanning bed epidemic: time for action. J Natl Compr Canc Netw 2012; 10:1311-4. PubMed
  • Anghel SI, Correa-Rochal R, Budinska E, Boliganl KF, Abraham S, Colombetti S, Fontao L, Mariotti A, Rimoldi D, Ghanem GE, Fisher DE, Lévy F, Delorenzi M, Piguet V. Breast cancer suppressor candidate-1 (BCSC-1) is a melanoma tumor suppressor that down regulates MITF. Pigment Cell Melanoma Res 2012; 25:482-7. PubMed
  • Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev 2012; 26:1131-55. PubMed
  • Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 2012; 12:349-61. PubMed
  • Amrein PC, Attar EC, Takvorian RW, Hochberg EP, Ballen KK, Leahy KM, Fisher DE, Lacasce AS, Jacobsen ED, Armand P, Hasserjian RP, Werner L, Neuberg DS, Brown JR. Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. Clin Cancer Res 2011. PubMed
  • Mitra D, Robinson KC, Fisher DE. Melanoma and viagra: an unexpected connection. Pigment Cell Melanoma Res 2011; 24:16-8. PubMed
  • D'Orazio J, Fisher DE. Central role for cAMP signaling in pigmentation and UV resistance. Cell Cycle 2011; 10:8-9. PubMed
  • Ko JM, Fisher DE. A new era: melanoma genetics and therapeutics. J Pathol 2010; 223:241-50. PubMed
  • Levy C, Fisher DE. Dual roles of lineage restricted transcription factors: The case of MITF in melanocytes. Transcr 2011; 2:19-22. PubMed
  • Levy C, Khaled M, Iliopoulos D, Janas MM, Schubert S, Pinner S, Chen PH, Li S, Fletcher AL, Yokoyama S, Scott KL, Garraway LA, Song JS, Granter SR, Turley SJ, Fisher DE, Novina CD. Intronic miR-211 Assumes the Tumor Suppressive Function of Its Host Gene in Melanoma. Mol Cell 2010; 40:841-849. PubMed
  • Liu JJ, Fisher DE. Lighting a path to pigmentation: mechanisms of MITF induction by UV. Pigment Cell Melanoma Res 2010; 23:741-5. PubMed
  • Khaled M, Levy C, Fisher DE. Control of melanocyte differentiation by a MITF-PDE4D3 homeostatic circuit. Genes Dev 2010; 24:2276-81. PubMed
  • Fisher DE, James WD. Indoor tanning--science, behavior, and policy. N Engl J Med 2010; 363:901-3. PubMed
  • Garibyan L, Fisher DE. How sunlight causes melanoma. Curr Oncol Rep 2010; 12:319-26. PubMed
  • Weinstock MA, Fisher DE. Indoor ultraviolet tanning: what the data do and do not show regarding risk of melanoma and keratinocyte malignancies. J Natl Compr Canc Netw 2010; 8:867-73. PubMed
  • Park JM, Fisher DE. Testimony from the bedside: from Coley's toxins to targeted immunotherapy. Cancer Cell 2010; 18:9-10. PubMed
  • Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H, Wargo JA. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010; 70:5213-9. PubMed
  • Weinberg R, Fisher DE, Rich J. Dynamic and transient cancer stem cells nurture melanoma. Nat Med 2010; 16:758. PubMed
  • Levy C, Khaled M, Robinson KC, Veguilla RA, Chen PH, Yokoyama S, Makino E, Lu J, Larue L, Beermann F, Chin L, Bosenberg M, Song JS, Fisher DE. Lineage-specific transcriptional regulation of DICER by MITF in melanocytes. Cell 2010; 141:994-1005. PubMed
  • Stewart RA, Sanda T, Widlund HR, Zhu S, Swanson KD, Hurley AD, Bentires-Alj M, Fisher DE, Kontaridis MI, Look AT, Neel BG. Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis. Dev Cell 2010; 18:750-62. PubMed
  • Gordon PM, Fisher DE. Role for the pro-apoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT dependent gastrointestinal stromal tumor cell line. J Biol Chem 2010; 285:14109-14. PubMed
  • Berger MF, Levin JZ, Vijayendran K, Sivachenko A, Adiconis X, Maguire J, Johnson LA, Robinson J, Verhaak RG, Sougnez C, Onofrio RC, Ziaugra L, Cibulskis K, Laine E, Barretina J, Winckler W, Fisher DE, Getz G, Meyerson M, Jaffe DB, Gabriel SB, Lander ES, Dummer R, Gnirke A, Nusbaum C, Garraway LA. Integrative analysis of the melanoma transcriptome. Genome Res 2010; 20:413-27. PubMed
  • Jané-Valbuena J, Widlund HR, Perner S, Johnson LA, Dibner AC, Lin WM, Baker AC, Nazarian RM, Vijayendran KG, Sellers WR, Hahn WC, Duncan LM, Rubin MA, Fisher DE, Garraway LA. An oncogenic role for ETV1 in melanoma. Cancer Res 2010; 70:2075-84. PubMed
  • Nishimura EK, Suzuki M, Igras V, Du J, Lonning S, Miyachi Y, Roes J, Beermann F, Fisher DE. Key roles for transforming growth factor beta in melanocyte stem cell maintenance. Cell Stem Cell 2010; 6:130-40. PubMed
  • Davis IJ, McFadden AW, Zhang Y, Coxon A, Burgess TL, Wagner AJ, Fisher DE. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Cancer Res 2010; 70:639-45. PubMed
  • Yokoyama S, Salma N, Fisher DE. MITF pathway mutations in melanoma. Pigment Cell Melanoma Res 2009; 22:376-7. PubMed
  • Scott KL, Kabbarah O, Liang MC, Ivanova E, Anagnostou V, Wu J, Dhakal S, Wu M, Chen S, Feinberg T, Huang J, Saci A, Widlund HR, Fisher DE, Xiao Y, Rimm DL, Protopopov A, Wong KK, Chin L. GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature 2009; 459:1085-90. PubMed
  • Zhao X,Graves C,Ames SJ,Fisher DE,Spanjaard RA. Mechanism of Regulation and Suppression of Melanoma Invasiveness by Novel Retinoic Acid Receptor-{gamma} Target Gene Carbohydrate Sulfotransferase 10. Cancer Res 2009; 69:5218-25. PubMed
  • Fisher DE. Advances in melanoma. Preface. Hematol Oncol Clin North Am 2009; 23:xiii-xiv. PubMed
  • Mitra D,Fisher DE. Transcriptional regulation in melanoma. Hematol Oncol Clin North Am 2009; 23:447-65, viii. PubMed
  • Schulman JM, Fisher DE. Indoor ultraviolet tanning and skin cancer: health risks and opportunities. Curr Opin Oncol 2009; 21:144-9. PubMed
  • Robinson KC,Fisher DE. Specification and loss of melanocyte stem cells. Semin Cell Dev Biol 2009; 20:111-6. PubMed
  • Jiang X,Zhou J,Yuen NK,Corless CL,Heinrich MC,Fletcher JA,Demetri GD,Widlund HR,Fisher DE,Hodi FS. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 2008; 14:7726-32. PubMed
  • Hodi FS,Fisher DE. Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma. Nat Clin Pract Oncol 2008; 5:696-7. PubMed
  • Ozsolak F,Poling LL,Wang Z,Liu H,Liu XS,Roeder RG,Zhang X,Song JS,Fisher DE. Chromatin structure analyses identify miRNA promoters. Genes Dev 2008; 22:3172-83. PubMed
  • Osawa M,Fisher DE. Notch and melanocytes: diverse outcomes from a single signal. J Invest Dermatol 2008; 128:2571-4. PubMed
  • Tran TT,Schulman J,Fisher DE. UV and pigmentation: molecular mechanisms and social controversies. Pigment Cell Melanoma Res 2008; 21:509-16. PubMed
  • Yokoyama S,Feige E,Poling LL,Levy C,Widlund HR,Khaled M,Kung AL,Fisher DE. Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. Pigment Cell Melanoma Res 2008; 21:457-63. PubMed
  • Friedberg J, Jacobsen E, Neuberg D, Kutok J, Munoz O, Boussiotis V, Reynolds H, Fisher D, Szot A, Van Den Abbeele A, Freedman A. Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept. Leuk Lymphoma 2008; 49:902-9. PubMed
  • Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008; 26:2046-51. PubMed
  • Sato-Jin K, Nishimura EK, Akasaka E, Huber W, Nakano H, Miller A, Du J, Wu M, Hanada K, Sawamura D, Fisher DE, Imokawa G. Epistatic connections between microphthalmia-associated transcription factor and endothelin signaling in Waardenburg syndrome and other pigmentary disorders. FASEB J 2007; 22:1155-68. PubMed
  • Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008; 14:418-25. PubMed
  • Fisher DE, Medrano EE, McMahon M, Soengas MS, Schuchter L, Wolchok JD, Merlino G. Meeting Report: Fourth International Congress of the Society for Melanoma Research. Pigment Cell Melanoma Res 2008; 21:15-26. PubMed
  • Kawakami A, Sakane F, Imai S, Yasuda S, Kai M, Kanoh H, Jin HY, Hirosaki K, Yamashita T, Fisher DE, Jimbow K. Rab7 regulates maturation of melanosomal matrix protein gp100/Pmel17/Silv. J Invest Dermatol 2007; 128:143-50. PubMed
  • Edwards CJ, Cooper C, Fisher D, Field M, van Staa TP, Arden NK. The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57:1151-7. PubMed
  • Widlund HR, Fisher DE. Potent p53-independent tumor suppressor activity of ARF in melanoma-genesis. Pigment Cell Res 2007; 20:339-40. PubMed
  • Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P, Nadler LM, Freedman AS. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant 2007; 13:1057-65. PubMed
  • Ballen KK, Shpall EJ, Avigan D, Yeap BY, Fisher DC, McDermott K, Dey BR, Attar E, McAfee S, Konopleva M, Antin JH, Spitzer TR. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant 2007; 13:838-43. PubMed
  • Cui R, Widlund HR, Feige E, Lin JY, Wilensky DL, Igras VE, D'Orazio J, Fung CY, Schanbacher CF, Granter SR, Fisher DE. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell 2007; 128:853-64. PubMed
  • Lin JY, Fisher DE. Melanocyte biology and skin pigmentation. Nature 2007; 445:843-50. PubMed
  • Ozsolak F, Song JS, Liu XS, Fisher DE. High-throughput mapping of the chromatin structure of human promoters. Nat Biotechnol 2007; 25:244-8. PubMed
  • Tsuda M, Davis IJ, Argani P, Shukla N, McGill GG, Nagai M, Saito T, La. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 2007; 67:919-29. PubMed
  • Chang EJ, Kim HJ, Ha J, Kim HJ, Ryu J, Park KH, Kim UH, Lee ZH, Kim HM, Fisher DE, Kim HH. Hyaluronan inhibits osteoclast differentiation via Toll-like receptor 4. J Cell Sci 2006; 120:166-76. PubMed
  • D'Orazio JA, Nobuhisa T, Cui R, Arya M, Spry M, Wakamatsu K, Igras V, Kunisada T, Granter SR, Nishimura EK, Ito S, Fisher DE. Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. Nature 2006; 443:340-4. PubMed
  • Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 2006; 12:406-14. PubMed
  • Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006; 20:2149-82. PubMed
  • Davis IJ, Kim JJ, Ozsolak F, Widlund HR, Rozenblatt-Rosen O, Granter SR, Du J, Fletcher JA, Denny CT, Lessnick SL, Linehan WM, Kung AL, Fisher DE. Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. Cancer Cell 2006; 9:473-84. PubMed
  • McGill GG, Haq R, Nishimura EK, Fisher DE. c-Met expression is regulated by Mitf in the melanocyte lineage. J Biol Chem 2006; 281:10365-73. PubMed
  • Mukohara T, Civiello G, Davis IJ, Taffaro ML, Christensen J, Fisher DE, Johnson BE, J. Inhibition of the met receptor in mesothelioma. Clin Cancer Res 2005; 11:8122-30. PubMed
  • Kim K, Kim JH, Lee J, Jin HM, Lee SH, Fisher DE, Kook H, Kim KK, Choi Y, Kim N. Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J Biol Chem 2005; 280:35209-16. PubMed
  • Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005; 436:117-22. PubMed
  • Mertens F, Fletcher CD, Antonescu CR, Coindre JM, Colecchia M, Domanski HA, Downs-Kelly E, Fisher C, Goldblum JR, Guillou L, Reid R, Rosai J, Sciot R, Mandahl N, Panagopoulos I. Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene. Lab Invest 2005; 85:408-15. PubMed
  • Hershey CL, Fisher DE. Genomic analysis of the Microphthalmia locus and identification of the MITF-J/Mitf-J isoform. Gene 2005; 347:73-82. PubMed
  • Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD, Berghmans S, Mayhall EA, Traver D, Fletcher CD, Aster JC, Granter SR, Look AT, Lee C, Fisher DE, Zon LI. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol 2005; 15:249-54. PubMed
  • Nishimura EK, Granter SR, Fisher DE. Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche. Science 2004; 307:720-4. PubMed
  • Argani P, La. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol 2005; 29:230-40. PubMed
  • Miller AJ, Levy C, Davis IJ, Razin E, Fisher DE. Sumoylation of MITF and its related family members TFE3 and TFEB. J Biol Chem 2004; 280:146-55. PubMed
  • Garraway LA, Weir BA, Zhao X, Widlund H, Beroukhim R, Berger A, Rimm D, Rubin MA, Fisher DE, Meyerson ML, Sellers WR. "Lineage Addiction" in Human Cancer: Lessons from Integrated Genomics. Cold Spring Harb Symp Quant Biol 2006; 70:25-34. PubMed
  • Garraway LA, Weir BA, Zhao X, Widlund H, Beroukhim R, Berger A, Rimm D, Rubin MA, Fisher DE, Meyerson ML, Sellers WR. "Lineage Addiction" in Human Cancer: Lessons from Integrated Genomics. Cold Spring Harb Symp Quant Biol 2005; 70:1-10. PubMed
  • Miller AJ, Du J, Rowan S, Hershey CL, Widlund HR, Fisher DE. Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma. Cancer Res 2004; 64:509-16. PubMed
  • Du J, Miller AJ, Widlund HR, Horstmann MA, Ramaswamy S, Fisher DE. MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Am J Pathol 2003; 163:333-43. PubMed
  • Davis IJ, Hsi BL, Arroyo JD, Vargas SO, Yeh YA, Motyckova G, Valencia P, Perez-Atayde AR, Argani P, Ladanyi M, Fletcher JA, Fisher DE. Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. Proc Natl Acad Sci U S A 2003; 100:6051-6. PubMed
  • Selzer E, Thallinger C, Hoeller C, Oberkleiner P, Wacheck V, Pehamberger H, Jansen B. Betulinic acid-induced Mcl-1 expression in human melanoma--mode of action and functional significance. Mol Med 2003; 8:877-84. PubMed
  • Sheffield MV, Yee H, Dorvault CC, Weilbaecher KN, Eltoum IA, Siegal GP, Fisher DE, Chhieng DC. Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations. Am J Clin Pathol 2002; 118:930-6. PubMed
  • Baksh S, Widlund HR, Frazer-Abel AA, Du J, Fosmire S, Fisher DE, DeCaprio JA, Modiano JF, Burakoff SJ. NFATc2-mediated repression of cyclin-dependent kinase 4 expression. Mol Cell 2002; 10:1071-81. PubMed
  • Widlund HR, Horstmann MA, Price ER, Cui J, Lessnick SL, Wu M, He X, Fisher DE. Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. J Cell Biol 2002; 158:1079-87. PubMed
  • Motyckova G, Fisher DE. Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease. Curr Mol Med 2002; 2:407-21. PubMed
  • McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, Nishimura EK, Lin YL, Ramaswamy S, Avery W, Ding HF, Jordan SA, Jackson IJ, Korsmeyer SJ, Golub TR, Fisher DE. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 2002; 109:707-18. PubMed
  • Selzer E, Wacheck V, Lucas T, Heere-Ress E, Wu M, Weilbaecher KN, Schlegel W, Valent P, Wrba F, Pehamberger H, Fisher D, Jansen B. The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma. Cancer Res 2002; 62:2098-103. PubMed
  • Granter SR, Weilbaecher KN, Quigley C, Fisher DE. Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma. Appl Immunohistochem Mol Morphol 2002; 10:47-51. PubMed
  • Ding HF, Fisher DE. Induction of apoptosis in cancer: new therapeutic opportunities. Ann Med 2003; 34:451-69. PubMed
  • Dorvault CC, Weilbaecher KN, Yee H, Fisher DE, Chiriboga LA, Xu Y, Chhieng DC. Microphthalmia transcription factor: a sensitive and specific marker for malignant melanoma in cytologic specimens. Cancer 2001; 93:337-43. PubMed
  • Weilbaecher KN, Motyckova G, Huber WE, Takemoto CM, Hemesath TJ, Xu Y, Hershey CL, Dowland NR, Wells AG, Fisher DE. Linkage of M-CSF signaling to Mitf, TFE3, and the osteoclast defect in Mitf(mi/mi) mice. Mol Cell 2001; 8:749-58. PubMed
  • Fisher DE. Pathways of apoptosis and the modulation of cell death in cancer. Hematol Oncol Clin North Am 2002; 15:931-56, ix. PubMed
  • Bates RC, Edwards NS, Burns GF, Fisher DE. A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer Res 2001; 61:5275-83. PubMed
  • Granter SR, Weilbaecher KN, Quigley C, Fletcher CD, Fisher DE. Microphthalmia transcription factor: not a sensitive or specific marker for the diagnosis of desmoplastic melanoma and spindle cell (non-desmoplastic) melanoma. Am J Dermatopathol 2001; 23:185-9. PubMed
  • Ding HF, Fisher DE. p53, caspase 8, and regulation of apoptosis after ionizing radiation. J Pediatr Hematol Oncol 2001; 23:185-8. PubMed
  • Pruschy M, Rocha S, Zaugg K, Tenzer A, Hess C, Fisher DE, Glanzmann C, Bodis S. Key targets for the execution of radiation-induced tumor cell apoptosis: the role of p53 and caspases. Int J Radiat Oncol Biol Phys 2001; 49:561-7. PubMed
  • Fisher DE. The p53 tumor suppressor: critical regulator of life & death in cancer. Apoptosis 2001; 6:7-15. PubMed
  • King R, Googe PB, Weilbaecher KN, Mihm MC, Fisher DE. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors. Am J Surg Pathol 2001; 25:51-7. PubMed
  • Granter SR, Weilbaecher KN, Quigley C, Fletcher CD, Fisher DE. Clear cell sarcoma shows immunoreactivity for microphthalmia transcription factor: further evidence for melanocytic differentiation. Mod Pathol 2001; 14:6-9. PubMed
  • Ding HF, Lin YL, McGill G, Juo P, Zhu H, Blenis J, Yuan J, Fisher DE. Essential role for caspase-8 in transcription-independent apoptosis triggered by p53. J Biol Chem 2000; 275:38905-11. PubMed
  • Fisher DE. Turning p53 on or off: either way may treat cancer. Drug Resist Updat 2001; 3:77-79. PubMed
  • Weiden PL, Breitz HB, Press O, Appelbaum JW, Bryan JK, Gaffigan S, Stone D, Axworthy D, Fisher D, Reno J. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm 2000; 15:15-29. PubMed
  • Sellers WR, Fisher DE. Apoptosis and cancer drug targeting. J Clin Invest 1999; 104:1655-61. PubMed
  • Arbiser JL, Raab G, Rohan RM, Paul S, Hirschi K, Flynn E, Price ER, Fisher DE, Cohen C, Klagsbrun M. Isolation of mouse stromal cells associated with a human tumor using differential diphtheria toxin sensitivity. Am J Pathol 1999; 155:723-9. PubMed
  • King R, Weilbaecher KN, McGill G, Cooley E, Mihm M, Fisher DE. Microphthalmia transcription factor. A sensitive and specific melanocyte marker for MelanomaDiagnosis. Am J Pathol 1999; 155:731-8. PubMed
  • Swingler S, Mann A, Jacqu. HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat Med 1999; 5:997-103. PubMed
  • McGill G, Fisher DE. p53 and cancer therapy: a double-edged sword. J Clin Invest 1999; 104:223-5. PubMed
  • Hardenbergh PH, Hahnfeldt P, Hlatky L, Takemoto C, Shimamura A, McGill G, Fung CY, Bodis S, Fisher DE. Distinct mathematical behavior of apoptotic versus non-apoptotic tumor cell death. Int J Radiat Oncol Biol Phys 1999; 43:601-5. PubMed
  • Price ER, Horstmann MA, Wells AG, Weilbaecher KN, Takemoto CM, Landis MW, Fisher DE. alpha-Melanocyte-stimulating hormone signaling regulates expression of microphthalmia, a gene deficient in Waardenburg syndrome. J Biol Chem 1998; 273:33042-7. PubMed
  • Ding HF, McGill G, Rowan S, Schmaltz C, Shimamura A, Fisher DE. Oncogene-dependent regulation of caspase activation by p53 protein in a cell-free system. J Biol Chem 1998; 273:28378-83. PubMed
  • Schmaltz C, Hardenbergh PH, Wells A, Fisher DE. Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol Cell Biol 1998; 18:2845-54. PubMed
  • Weilbaecher KN, Hershey CL, Takemoto CM, Horstmann MA, Hemesath TJ, Tashjian AH, Fisher DE. Age-resolving osteopetrosis: a rat model implicating microphthalmia and the related transcription factor TFE3. J Exp Med 1998; 187:775-85. PubMed
  • Westphal CH, Rowan S, Schmaltz C, Elson A, Fisher DE, Leder P. atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity. Nat Genet 1997; 16:397-401. PubMed
  • Soiffer RJ, Fairclough D, Robertson M, Alyea E, Anderson K, Freedman A, Bartlett-Pandite L, Fisher D, Schlossman RL, Stone R, Murray C, Freeman A, Marcus K, Mauch P, Nadler L, Ritz J. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood 1997; 89:3039-47. PubMed
  • McCormick RJ, Badalian T, Fisher DE. The leucine zipper may induce electrophoretic mobility anomalies without DNA bending. Proc Natl Acad Sci U S A 1996; 93:14434-9. PubMed
  • Fung CY, Fisher DE. p53: from molecular mechanisms to prognosis in cancer. J Clin Oncol 1995; 13:808-11. PubMed
  • Parvin JD, McCormick RJ, Sharp PA, Fisher DE. Pre-bending of a promoter sequence enhances affinity for the TATA-binding factor. Nature 1995; 373:724-7. PubMed
  • Hemesath TJ, Steingr. microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev 1994; 8:2770-80. PubMed
  • Fisher DE, Parent LA, Sharp PA. High affinity DNA-binding Myc analogs: recognition by an alpha helix. Cell 1993; 72:467-76. PubMed
  • Fisher DE, Parent LA, Sharp PA. Myc/Max and other helix-loop-helix/leucine zipper proteins bend DNA toward the minor groove. Proc Natl Acad Sci U S A 1992; 89:11779-83. PubMed
  • Reeves WH, Fisher DE, Wisniewolski R, Gottlieb AB, Chiorazzi N. Psoriasis and Raynaud's phenomenon associated with autoantibodies to U1 and U2 small nuclear ribonucleoproteins. N Engl J Med 1986; 315:105-11. PubMed
  • Fisher DE, Conner GE, Reeves WH, Wisniewolski R, Blobel G. Small nuclear ribonucleoprotein particle assembly in vivo: demonstration of a 6S RNA-free core precursor and posttranslational modification. Cell 1985; 42:751-8. PubMed
  • Fisher DE, Reeves WH, Conner GE, Blobel G, Kunkel HG. Pulse labeling of small nuclear ribonucleoproteins in vivo reveals distinct patterns of antigen recognition by human autoimmune antibodies. Proc Natl Acad Sci U S A 1984; 81:3185-9. PubMed
Hide